Skip to main content
SpringerLink
Log in

Schwerpunkt Hodgkin-Lymphom

Behandlung des refraktären/rezidivierten Hodgkin-Lymphoms

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

Lesen Sie in der folgenden Übersicht, wie vorzugehen ist, wenn der Verdacht auf ein Rezidiv eines Hodgkin-Lymphoms besteht und welche Therapieoptionen zur Verfügung stehen. Hier werden Chemotherapieschemata genauso thematisiert wie die zielgerichtete Therapie und immuntherapeutische Verfahren.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. Linch DC et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–4

    Article  CAS  Google Scholar 

  2. Schmitz N et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71

    Article  CAS  Google Scholar 

  3. Bröckelmann PJ et al. Hodgkin Lymphoma in Adults. Dtsch Arztebl Int. 2018;115(31-32):535–40

    PubMed  Google Scholar 

  4. Josting A et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2005;23(7):1522–9

    Article  Google Scholar 

  5. Bröckelmann PJ et al. T032 (0130) Relapse after early-stage favorable Hodgkin Lymphoma: Disease characteristics, treatment strategies and their outcome. HemaSphere. 2018;2(S3):44

    Google Scholar 

  6. Josting A et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol. 2002;13(10):1628–35

    Article  CAS  Google Scholar 

  7. Bröckelmann PJ et al. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017;28(6):1352–8

    Article  Google Scholar 

  8. Morschhauser F et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008;26(36):5980–7

    Article  Google Scholar 

  9. Sibon D et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica. 2016;101(4):474–81

    Article  Google Scholar 

  10. Moskowitz CH et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62

    Article  CAS  Google Scholar 

  11. Moskowitz CH et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–42

    Article  CAS  Google Scholar 

  12. Josting A et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol. 2010;28(34):5074–80

    Article  Google Scholar 

  13. Arai S et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531–3

    Article  Google Scholar 

  14. Younes A et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9

    Article  CAS  Google Scholar 

  15. Gopal AK et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(8):1236–43

    Article  CAS  Google Scholar 

  16. Armand P et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428–39

    Article  CAS  Google Scholar 

  17. Younes A et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–94

    Article  CAS  Google Scholar 

  18. Chen R et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017;35(19):2125–32

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik I für Innere Medizin, Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf, Universität zu Köln, Köln, Deutschland

    Sarah Gillessen & Bastian von Tresckow

  2. German Hodgkin Study Group (GHSG), Köln, Deutschland

    Sarah Gillessen & Bastian von Tresckow

  3. Klinik I für Innere Medizin, Universitätsklinikum Köln, German Hodgkin Study Group (GHSG), Kerpener Straße 62, 50937, Köln, Deutschland

    Sarah Gillessen

Authors
  1. Sarah Gillessen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bastian von Tresckow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Gillessen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gillessen, S., von Tresckow, B. Behandlung des refraktären/rezidivierten Hodgkin-Lymphoms. Info Onkol. 22, 16–20 (2019). https://doi.org/10.1007/s15004-019-6700-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6700-0

Search

Navigation